PatientsVille.com LogoPatientsVille.com

Cough | Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment

Cough research study

What is the primary objective of this study?

The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.

Who is eligible to participate?

Inclusion Criteria: 1. Patients must be able to understand the study procedures agree to participate and give written consent. 2. Patients with productive cough as result an acute URTI (i.e., cold or flu) or allergic cough in the last 10 day. 3. Cough score superior to 3. Exclusion Criteria: 1. Pregnancy or risk of pregnancy. 2. Lactation. 3. Fever above 38ยบ C. 4. Patients with bacterial infections of the upper respiratory tract. 5. Any pathology or past medical condition that can interfere with this protocol.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Cough

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Syrup of oxomemazine, guaifenesin and potassium iodate5ml each 4 hours

Drug:Syrup of guaifenesin5ml each 4 hours

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

DRUG 1Syrup of oxomemazine, guaifenesin and potassium iodate

DRUG 2Syrup of guaifenesin

Study Status

Unknown status

Start Date: February 2013

Completed Date: September 2013

Phase: Phase 3

Type: Interventional

Design:

Primary Outcome: Reduction/improvement of cough symptoms

Secondary Outcome: Tolerance

Study sponsors, principal investigator, and references

Principal Investigator: Felipe Pinho, MD

Lead Sponsor: EMS

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01257243

Discuss Mucinex